Moreover, KANK1 has been discovered to fuse with neurotrophic receptor tyrosine kinase 3 (NTRK3) gene in patient samples with pathologically confirmed metanephric adenoma leading to a subset of B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutations [47]. The gene discussed is MARK2; the disease is metanephric adenoma.